DE3131146A1
(de)
*
|
1981-08-06 |
1983-02-24 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
|
DE3300933A1
(de)
*
|
1983-01-13 |
1984-07-19 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
|
DE3319027A1
(de)
*
|
1983-05-26 |
1984-11-29 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
|
US20030036980A1
(en)
*
|
2001-08-14 |
2003-02-20 |
Wren Stephen C. |
System for marketing goods and services utilizing computerized central and remote facilities
|
US5405863A
(en)
*
|
1992-12-01 |
1995-04-11 |
Smithkline Beecham Corporation |
Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
|
ZA938897B
(en)
*
|
1992-12-01 |
1994-08-01 |
Smithkline Beecham Corp |
Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
|
WO1994020096A1
(en)
*
|
1993-03-05 |
1994-09-15 |
Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited |
Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
|
US5308862A
(en)
*
|
1993-03-05 |
1994-05-03 |
Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 |
Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
|
US5393772A
(en)
*
|
1993-11-24 |
1995-02-28 |
Boehringer Mannheim Pharmaceuticals Corporation |
Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
|
US5760069A
(en)
|
1995-02-08 |
1998-06-02 |
Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 |
Method of treatment for decreasing mortality resulting from congestive heart failure
|
US6075040A
(en)
*
|
1996-09-05 |
2000-06-13 |
Eli Lilly And Company |
Selective β3 adrenergic agonists
|
ZA967892B
(en)
*
|
1995-09-21 |
1998-03-18 |
Lilly Co Eli |
Selective β3 adrenergic agonists.
|
US6177430B1
(en)
|
1997-03-27 |
2001-01-23 |
Pfizer Inc |
Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
|
DE19628335A1
(de)
*
|
1996-07-13 |
1998-01-15 |
Boehringer Mannheim Gmbh |
Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
|
ZA977565B
(en)
*
|
1996-08-23 |
1999-02-17 |
Boehringer Mannheim Pharm Corp |
Method for inhibiting the expression of fas
|
EP0827746B1
(de)
*
|
1996-09-05 |
2002-04-03 |
Eli Lilly And Company |
Carbazolanaloge als selektive beta3-adrenergische Agonisten
|
JP2002512591A
(ja)
*
|
1996-10-09 |
2002-04-23 |
ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション―スミスクライン・ビーチャム・コーポレイション・リミテッド・パートナーシップ・ナンバー1 |
ストレス活性化されたタンパク質キナーゼの阻害法
|
EP0893440A1
(de)
*
|
1997-07-22 |
1999-01-27 |
Roche Diagnostics GmbH |
Eine thermodynamisch stabile Modifikation von 1-(4-Carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]- 2-propanole, Verfahren zu ihrer Herstellung und ihre enthaltende Arznemittel
|
US6730326B2
(en)
|
1997-07-22 |
2004-05-04 |
Roche Diagnostics Gmbh |
Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
|
ZA989365B
(en)
*
|
1997-10-15 |
1999-04-15 |
Boehringer Mannheim Pharm Corp |
Preparation for treating alzheimer's disease
|
CN1285738A
(zh)
*
|
1997-11-12 |
2001-02-28 |
泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 |
卡维地洛的新的口服剂型
|
HU227441B1
(en)
*
|
1997-11-24 |
2011-06-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Process for producing carvedilol, enantiomers and salts thereof
|
CO5011072A1
(es)
|
1997-12-05 |
2001-02-28 |
Lilly Co Eli |
Etanolaminas pirazinil substituidas como agfonistas de los receptores
|
EP0968714A1
(de)
*
|
1998-07-02 |
2000-01-05 |
Roche Diagnostics GmbH |
Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
|
ATE246502T1
(de)
*
|
1998-04-09 |
2003-08-15 |
Roche Diagnostics Gmbh |
Arzneiformen enthaltend carvedilol
|
US6664284B2
(en)
|
1998-07-23 |
2003-12-16 |
Roche Diagnostics Gmbh |
Stabilized carvedilol injection solution
|
DE19833119A1
(de)
*
|
1998-07-23 |
2000-01-27 |
Roche Diagnostics Gmbh |
Spritzfertige Injektionslösungen enthaltend Carvedilol
|
WO2000007584A2
(en)
|
1998-08-04 |
2000-02-17 |
Wisconsin Alumni Research Foundation |
Method of reducing retinal ganglion cell degeneration
|
PE20001302A1
(es)
|
1998-11-27 |
2000-11-30 |
Hoffmann La Roche |
Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
|
MY125942A
(en)
|
1999-09-07 |
2006-09-29 |
Upjohn Co |
Aminoalkoxy carbazoles for the treatment of cns diseases
|
EP1233768A1
(de)
|
1999-11-15 |
2002-08-28 |
Smithkline Beecham |
Carvedilolmethansulphonat
|
US20010036959A1
(en)
*
|
2000-04-03 |
2001-11-01 |
Gabel Rolf Dieter |
Carvedilol-hydrophilic solutions
|
DE60105996T2
(de)
*
|
2000-04-03 |
2006-03-09 |
F. Hoffmann-La Roche Ag |
Konzentrierte lösungen von carvedilol
|
DK174645B1
(da)
*
|
2000-05-18 |
2003-08-04 |
Gea Farmaceutisk Fabrik As |
Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
|
EP1655285A1
(de)
*
|
2000-06-28 |
2006-05-10 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur Herstellung einer kristallinen Form von Carvedilol (Form II)
|
IL153688A0
(en)
*
|
2000-06-28 |
2003-07-06 |
Teva Pharma |
Carvedilol
|
GB0106953D0
(en)
*
|
2001-03-20 |
2001-05-09 |
Univ Aberdeen |
Neufofibrillary labels
|
JP2004525941A
(ja)
*
|
2001-04-02 |
2004-08-26 |
スミスクライン・ビーチャム・コーポレイション |
治療方法
|
IN191028B
(de)
*
|
2001-05-17 |
2003-09-13 |
Sun Pharmaceutical Ind Ltd |
|
ATE328595T1
(de)
*
|
2001-07-13 |
2006-06-15 |
Smithkline Beecham Corp |
Carvedilolpolymorph
|
US20040234602A1
(en)
|
2001-09-21 |
2004-11-25 |
Gina Fischer |
Polymer release system
|
WO2003024430A1
(en)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Morphine polymer release system
|
WO2003029214A1
(en)
*
|
2001-09-28 |
2003-04-10 |
F. Hoffmann-La Roche Ag |
Pseudopolymorphic forms of carvedilol
|
WO2003028718A1
(en)
*
|
2001-10-01 |
2003-04-10 |
Smithkline Beecham Corporation |
Novel formulations of carvedilol
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
KR20040077872A
(ko)
|
2002-01-15 |
2004-09-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
카베디롤의 결정질 고체 및 그 제조 방법
|
EP2266590A3
(de)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
|
AU2003231283A1
(en)
*
|
2002-04-30 |
2003-11-17 |
Sb Pharmco Puerto Rico Inc. |
Carvedilol monocitrate monohydrate
|
EP1501502A2
(de)
*
|
2002-05-03 |
2005-02-02 |
SmithKline Beecham Pharmco Puerto Rico, Inc. |
Carvedilol-pharmasolv-solvat
|
JP2005524701A
(ja)
*
|
2002-05-03 |
2005-08-18 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
カルベジロール処方
|
CN103254114A
(zh)
*
|
2002-06-27 |
2013-08-21 |
史密斯克莱.比奇曼(科克)有限公司 |
卡维地洛磷酸盐和/或其溶剂合物相应的组合物和/或治疗方法
|
WO2004002472A1
(en)
|
2002-06-27 |
2004-01-08 |
Sb Pharmco Puerto Rico Inc. |
Carvedilol hydrobromide
|
US20040152756A1
(en)
*
|
2002-07-15 |
2004-08-05 |
Wei Chen |
Carvedilol polymorph
|
EP1542728A4
(de)
*
|
2002-07-22 |
2005-09-21 |
Nanohybrid Co Ltd |
Hybrid von itraconazol, cyclosporin oder carvedilol mit einem geschichteten silikat und verfahren zu seiner herstellung
|
AU2003250483A1
(en)
|
2002-08-19 |
2004-03-11 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
US6632832B1
(en)
|
2002-09-10 |
2003-10-14 |
Dabur Research Foundation |
Anti-cancer activity of carvedilol and its isomers
|
SK285547B6
(sk)
*
|
2002-11-08 |
2007-03-01 |
Zentiva, A. S. |
Spôsob prípravy Carvedilolu
|
EP1562552A1
(de)
*
|
2002-11-08 |
2005-08-17 |
Egalet A/S |
Zusammensetzung zur kontrollierten wirkstoffabgabe von carvedilol
|
US7468442B2
(en)
*
|
2003-04-21 |
2008-12-23 |
Matrix Laboratories Ltd. |
Process for the preparation of carvedilol form-II
|
AU2004242777B2
(en)
*
|
2003-05-30 |
2011-05-12 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
US7482471B2
(en)
*
|
2003-06-20 |
2009-01-27 |
Sun Pharmaceutical Industries Limited |
Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
WO2005051322A2
(en)
|
2003-11-25 |
2005-06-09 |
Sb Pharmco Puerto Rico Inc. |
Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
|
US7750036B2
(en)
*
|
2003-11-25 |
2010-07-06 |
Sb Pharmco Puerto Rico Inc. |
Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
|
EP1686967A4
(de)
*
|
2003-11-25 |
2012-08-08 |
Smithkline Beecham Cork Ltd |
Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
|
WO2005115981A2
(en)
*
|
2004-04-22 |
2005-12-08 |
Usv Limited |
A process for the preparation of 1-(9h-carbazol-4-yloxy)-3-2-(-methoxyphenoxy)-ethyl amino-propan-2-ol
|
GB0411273D0
(en)
*
|
2004-05-20 |
2004-06-23 |
Cipla Ltd |
Process and product
|
JP2008521805A
(ja)
*
|
2004-11-30 |
2008-06-26 |
アーテシアン セラピューティクス, インコーポレイテッド |
β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
|
ATE445601T1
(de)
*
|
2004-12-09 |
2009-10-15 |
Zach System Spa |
Verfahren zur herstellung von carvedilol und seinen enantiomeren
|
US20070027202A1
(en)
*
|
2005-06-07 |
2007-02-01 |
Ashok Kumar |
Process for the preparation of carvedilol and its salts
|
EP1781611A1
(de)
*
|
2005-06-09 |
2007-05-09 |
Teva Pharmaceutical Industries Ltd. |
Kristalline formen des carvediols und verfahren zu ihrer herstellung
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
EP1945612A2
(de)
|
2005-10-13 |
2008-07-23 |
Orchid Research Laboratories Limited |
Heterocyclische verbindungen als pstat3/il-6-inhibitoren
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
CA2627599A1
(en)
*
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
TW200744583A
(en)
*
|
2006-03-14 |
2007-12-16 |
Ranbaxy Lab Ltd |
Statin stabilizing dosage formulations
|
US8703804B2
(en)
|
2006-03-26 |
2014-04-22 |
Uti Limited Partnership |
Ryanodine receptor inhibitors and methods relating thereto
|
EP1991527A2
(de)
*
|
2006-06-28 |
2008-11-19 |
Teva Pharmaceutical Industries Ltd |
Polymorphe formen von carvedilol-phosphat
|
CN101494980A
(zh)
*
|
2006-07-14 |
2009-07-29 |
兰贝克赛实验室有限公司 |
HMG-CoA还原酶抑制剂的多晶型形式及其应用
|
WO2008038301A1
(en)
*
|
2006-09-26 |
2008-04-03 |
Morepen Laboratories Limited |
A process for the preparation of carvedilol
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
US20090028935A1
(en)
*
|
2006-12-01 |
2009-01-29 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
WO2008070072A2
(en)
*
|
2006-12-01 |
2008-06-12 |
Mutual Pharmaceutical Company, Inc. |
Carvedilol forms, compositions, and methods of preparation thereof
|
WO2008084494A1
(en)
*
|
2007-01-08 |
2008-07-17 |
Matrix Laboratories Limited |
Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
|
CA2674536C
(en)
*
|
2007-01-16 |
2016-07-26 |
Egalet A/S |
Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
|
CZ302357B6
(cs)
*
|
2007-01-26 |
2011-03-30 |
Zentiva, A. S. |
Zpusob cištení Carvedilolu
|
EP2114881A1
(de)
*
|
2007-02-26 |
2009-11-11 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur reinigung von carvedilol oder von salzen davon
|
US20080249317A1
(en)
*
|
2007-04-04 |
2008-10-09 |
Apotex Inc. |
Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
|
WO2008142703A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Wanbury Limited |
A novel cost effective process for production of carvedilol phosphate
|
AU2008258596B2
(en)
|
2007-06-04 |
2013-02-14 |
Egalet Ltd |
Controlled release pharmaceutical compositions for prolonged effect
|
WO2009024997A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Lupin Limited |
Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
|
WO2009035535A2
(en)
*
|
2007-09-07 |
2009-03-19 |
Scinopharm Taiwan Ltd. |
Method of crystallizing carvedilol phosphate and the product thereof
|
US20090076116A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched carvediolo
|
US20090111998A1
(en)
*
|
2007-10-25 |
2009-04-30 |
Srinivas Reddy Gade |
Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
|
WO2009110004A1
(en)
|
2008-03-04 |
2009-09-11 |
Lupin Limited |
Stable pharmaceutical compositions qf carvedilol
|
WO2009115902A1
(en)
*
|
2008-03-19 |
2009-09-24 |
Cadila Pharmaceuticals Ltd. |
Process for the preparation of carvedilol via silyl protection of substituted amine
|
WO2009115906A2
(en)
*
|
2008-03-19 |
2009-09-24 |
Cadila Pharmaceuticals Ltd. |
An improved process for preparation of carvedilol involving halohydrin derivative
|
WO2009122425A1
(en)
*
|
2008-04-04 |
2009-10-08 |
Shodhana Laboratories Limited |
Novel crystalline form of carvedilol dihydrogen phosphate and related processes
|
US7763645B2
(en)
*
|
2008-05-23 |
2010-07-27 |
Wanbury Limited |
Carvedilol dihydrogen phosphate monohydrate
|
WO2010092589A2
(en)
*
|
2008-05-26 |
2010-08-19 |
Alkem Laboratories Ltd. |
Process for preparation of amorphous carvedilol phosphate
|
EP2393484A1
(de)
|
2009-02-06 |
2011-12-14 |
Egalet Ltd. |
Gegen missbrauch durch alkoholeinnahme widerstandsfähige zusammensetzung mit unmittelbarer freisetzung
|
EP2445487A2
(de)
|
2009-06-24 |
2012-05-02 |
Egalet Ltd. |
Retard-formulierungen
|
TWI415604B
(zh)
|
2009-09-29 |
2013-11-21 |
Tsh Biopharm Corp Ltd |
調控釋放卡菲蒂羅劑型
|
US20110229564A1
(en)
*
|
2010-03-22 |
2011-09-22 |
Amneal Pharmaceuticals, L.L.C. |
Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
|
EP2791199B1
(de)
|
2011-12-16 |
2015-09-16 |
3M Innovative Properties Company |
Oxiranhaltige bisanhydrohexitolderivate und verwendungen davon
|
NZ704011A
(en)
|
2012-07-06 |
2016-04-29 |
Egalet Ltd |
Abuse deterrent pharmaceutical compositions for controlled release
|
US8492426B1
(en)
*
|
2012-07-12 |
2013-07-23 |
Anis Ahmad |
Use of carvedilol for treatment of diabetes mellitus
|
AU2014255381A1
(en)
|
2013-04-17 |
2015-10-08 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
US10357476B1
(en)
|
2018-10-30 |
2019-07-23 |
Anis Ahmad |
Method for treating coronary artery disease
|
US11248001B2
(en)
|
2019-01-18 |
2022-02-15 |
Astrazeneca Ab |
PCSK9 inhibitors and methods of use thereof
|
CN111170997A
(zh)
*
|
2019-12-31 |
2020-05-19 |
广州医科大学 |
咔唑类化合物及其制备方法和应用
|
CN113372260A
(zh)
*
|
2021-07-05 |
2021-09-10 |
大连蒙迪科技有限公司 |
一种卡维地洛杂质的合成方法
|